As of September 27, 2026, RegenLab USA has an active Form S-1 registration statement on file with the SEC for an initial public offering on Nasdaq under the ticker RGNA, according to Renaissance Capital's report on September 25, 2026. The filing seeks to raise up to $35 million, with StoneX Financial Inc. acting as sole book-running manager. RegenLab USA is a regenerative-medicine device maker founded in Switzerland in 2003 and now based in Jersey City, New Jersey; it filed confidentially with the SEC on October 20, 2025, and reported $54 million in revenue for the 12 months ended June 30, 2026, Renaissance Capital said. TradingView's September 26, 2026 coverage described the S-1 as covering point-of-care platelet-rich plasma (PRP) and hyaluronic acid (HA) regenerative-medicine devices, with StoneX as sole bookrunner and no price range or share count specified yet. SEC EDGAR is the primary record for the US filing; Segmara does not sell, broker, or predict outcomes for any offering.
segmara.com publishes educational private-market context and can route limited interest into account-based private follow-up. Public pages do not create an offer, allocation, payment instruction, investment advice, or issuer-affiliated workflow.
Key points
A filed S-1, not yet a set date
RegenLab USA has an active Form S-1 registration statement on file with the SEC, seeking to raise up to $35 million and list on Nasdaq under the ticker RGNA, Renaissance Capital reported on September 25, 2026. StoneX Financial Inc. is acting as sole book-running manager. A filed S-1 is a real step toward a public listing, but it is not a confirmed date: the document does not yet include a price range or a share count, TradingView noted in its September 26, 2026 coverage.
From a confidential draft to a public filing
RegenLab USA first filed confidentially with the SEC on October 20, 2025, according to Renaissance Capital. Moving from a confidential draft to a public Form S-1 is itself a step forward, though neither a price range nor a listing date has been set as of the latest filing.
The company is based in Jersey City, New Jersey, and was founded in Switzerland in 2003, per the same report.
The business behind the ticker
RegenLab USA makes point-of-care regenerative-medicine devices built around platelet-rich plasma (PRP) and hyaluronic acid (HA), according to TradingView's September 26, 2026 description of the filing. Renaissance Capital reported the company booked $54 million in revenue for the 12 months ended June 30, 2026.
Track SEC EDGAR directly for the S-1's public filing record and any amendments; EDGAR covers only US filings, and a Nasdaq listing has not been finalized as of the latest review.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-regenlab-usa-ipo
Stable URL path for AI and search extraction.
Article title
When Will RegenLab USA IPO? Its S-1 Targets Nasdaq as RGNA
Main page topic.
Attached public sources
2
Number of citation links rendered at the bottom of the article.
Segmara listed companies
51
Live private-company listings in the public catalogue.
Priced listings
37
Catalogue listings with visible indicative or direct marks.
Request-quote listings
14
Catalogue listings where a public price is intentionally not invented.
Data fingerprint chart
Catalogue breadth100%
51 public listings
Visible pricing coverage72%
37 of 51 listings show a mark
Source depth48%
2 source links
Stage
Timing
Price / valuation signal
Interpretation
Chart metric
Score
Interpretation
Catalogue breadth
100 / 100
51 public listings
Visible pricing coverage
72 / 100
37 of 51 listings show a mark
Source depth
48 / 100
2 source links
Analytical lens
Search intent
The search behind 'When Will RegenLab USA IPO? Its S-1 Targets Nasdaq as RGNA' is an access-intent query. People want to know where they can start interest in RegenLab USA private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover private markets categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
BrowseRetail investor finds a private-company listing.
AccountBuyer creates one Segmara account.
RequestBuyer starts the private-share purchase request.
CloseAvailability, price, approvals, and final terms are handled privately.
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
Old-market frictionPrivate networks and institutional access
Segmara discoveryPublic listings retail buyers can browse
Account workflowOne account to start the purchase request
Private closeFinal terms handled after buyer interest
How private-share access starts on Segmara
RegenLab USA has a Form S-1 on file with the SEC as of Renaissance Capital's September 25, 2026 report, seeking to raise up to $35 million and list on Nasdaq under the ticker RGNA, with StoneX Financial as sole book-running manager.
The Jersey City, New Jersey-based company, founded in Switzerland in 2003, filed confidentially on October 20, 2025, and booked $54 million in revenue for the 12 months ended June 30, 2026, per Renaissance Capital.
TradingView reported on September 26, 2026 that the S-1 covers point-of-care PRP and HA regenerative-medicine devices, with no price range or share count set yet.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not listed can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential or public filing, so no step before pricing guarantees a listing.
Get the alert the day RegenLab USA files or prices
Free: every article, the IPO calendar and the weekly IPOs page. Pro: same-day filing alerts and the weekly brief on all 99 companies, with a 7-day free trial, then $15 a month. Research only, no share sales.
Can retail investors track private-company shares on Segmara?
Yes. Visitors can start with the free RegenLab USA tracker using email only, then decide whether a private follow-up makes sense. Availability, eligibility, pricing, allocation, transfer approval, documents, and final terms can still vary by route.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: visitors can follow named private-company interest before any account, document upload, or payment step.
What is the easiest next step?
Open the free RegenLab USA tracker first. It is email-only and keeps the public step narrow while final availability, pricing, eligibility, and terms are handled only through private follow-up.
Has RegenLab USA confirmed an IPO date?
No specific listing date has been confirmed. RegenLab USA filed a Form S-1 to list on Nasdaq under RGNA, according to Renaissance Capital's September 25, 2026 report, but the filing does not set a date, price range, or share count.
What does RegenLab USA make?
RegenLab USA makes point-of-care platelet-rich plasma (PRP) and hyaluronic acid (HA) regenerative-medicine devices, per TradingView's September 26, 2026 description of the S-1.
How much is RegenLab USA trying to raise, and who is running the deal?
The Form S-1 seeks to raise up to $35 million, with StoneX Financial Inc. named as sole book-running manager, according to Renaissance Capital.
Can I buy RegenLab USA shares before the IPO?
Not through Segmara. Segmara does not sell, broker, or arrange purchases of RegenLab USA shares, and any private-share offer you encounter should be verified independently before you rely on it.
Next step
Track private-market prices free.
If this article helped explain RegenLab USA, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account, and no allocation promise.
When a full account makes sense, Segmara can route limited interest into an account-based private follow-up. Availability, pricing, eligibility, allocation, transfer approval, liquidity, and final terms can vary by company and route.